Homoharringtonine induces apoptosis and growth arrest in human myeloma cells

References

• Jackson G, Einsele H, Moreau P, Miguel J S. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev 2005; 31: 591–602
   PubMed Web of Science ®Google Scholar
• Kyle R A, Rajkumar S V. Multiple myeloma. N Engl J Med 2004; 35: 1860–1873
   Web of Science ®Google Scholar
• Stanford B L, Zondor S D. Bortezomib treatment for multiple myeloma. Ann Pharmacother 2003; 37: 1825–1830
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Blood E, Vesole D, Fonseca R, Greipp P R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431–436
   PubMed Web of Science ®Google Scholar
• Warrel R P, Coonley C J, Gee T S. Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia. J Clin Oncol 1985; 3: 617–621
   PubMed Web of Science ®Google Scholar
• Luo C Y, Tang J Y, Wang Y P. Homoharringtonine: a new treatment option for myeloid leukemia. Hematology 2004; 9: 259–270
   PubMedGoogle Scholar
• Feldman E, Arlin Z, Ahmed T, Mittelman A, Puccio C, Chun H, et al. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia 1992; 6: 1185–1188
   PubMed Web of Science ®Google Scholar
• Feldman E, Arlin Z, Ahmed T, Mittelman A, Puccio C, Chun H, et al. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia 1992; 6: 1189–1191
   PubMed Web of Science ®Google Scholar
• Feldman E J, Seiter K P, Ahmed T, Baskind P, Arlin Z A. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia 1996; 10: 40–42
   PubMed Web of Science ®Google Scholar
• O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson L E, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995; 86: 3322–3326
   PubMed Web of Science ®Google Scholar
• O'Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreeff M, et al. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999; 93: 4149–4153
   PubMed Web of Science ®Google Scholar
• O'Brien S, Talpaz M, Cortes J, Shan J, Giles F J, Faderl S, et al. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 2002; 94: 2024–2032
   PubMed Web of Science ®Google Scholar
• Visani G, Russo D, Ottaviani E, Tosi P, Damiani D, Michelutti A, et al. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on ‘in vitro’ growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia 1997; 11: 624–628
   PubMed Web of Science ®Google Scholar
• Jin J, Jiang D Z, Mai W Y, Meng H T, Qian W B, Tong H Y, et al. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia 2006; 20: 1361–1367
   PubMed Web of Science ®Google Scholar
• Levy V, Zohar S, Bardin C, Vekhoff A, Chaoui D, Rio B, et al. A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br J Cancer 2006; 95: 253–259
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Talpaz M, Santini V, Murgo A, Cheson B, O'Brien S M. Homoharringtonine: history, current research, and future direction. Cancer 2001; 92: 1591–1605
   PubMed Web of Science ®Google Scholar
• Zhou J Y, Chen D L, Shen Z S, Koeffler H P. Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro. Cancer Res 1990; 50: 2031–2035
   PubMed Web of Science ®Google Scholar
• Ye X J, Lin M F. Homoharringtonine induces apoptosis of endothelium and down-regulates VEGF expression of K562 cells. J Zhejiang Univ Sci 2004; 5: 230–234
   PubMedGoogle Scholar
• Iwato K, Kawano M, Asaoku H, Tanabe O, Tanaka H, Kuramoto A. Separation of human myeloma cells from bone marrow aspirates in multiple myeloma and their proliferation and M-protein secretion in vitro. Blood 1988; 72: 562–566
   PubMed Web of Science ®Google Scholar
• Tassone P, Neri P, Burger R, Savino R, Shammas M, Catley L, et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu in vivo model of human multiple myeloma. Clin Cancer Res 2005; 11: 4251–4258
   PubMed Web of Science ®Google Scholar
• Yinjun L, Jie J, Weilai X, Xiangming T. Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP). Am J Hematol 2004; 76: 199–204
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Dixit V M. Death receptors: signaling and modulation. Science 1998; 281: 1305–1308
   PubMed Web of Science ®Google Scholar
• Adams J M, Cory S. The bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322–1326
   PubMed Web of Science ®Google Scholar
• Roth W, Reed J C. Apoptosis and cancer: when BAX is TRAILing away. Nat Med 2002; 8: 216–218
   PubMed Web of Science ®Google Scholar
• Cai Z, Lin M, Wuchter C, Ruppert V, Dorken B, Ludwig W D, et al. Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates bax translocation, mitochondrial cytochrome c release and caspase activation. Leukemia 2001; 15: 567–574
   PubMed Web of Science ®Google Scholar